ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1410

Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort

Connor Vershel1, Mark Hwang2, John Reveille3, Seokhun Kim4, Matthew A. Brown5, Michael Weisman6, Mariko Ishimori6 and Michael Ward7, 1Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston, TX, 2UTHealth Houston, Houston, TX, 3Department of Medicine, University of Texas Medical Center, Houston, TX, 4UTHealth Houston, Houston, 5Genomics England, London, United Kingdom, 6Cedars-Sinai Medical Center, LOS ANGELES, CA, 7National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD

Meeting: ACR Convergence 2025

Keywords: Ankylosing spondylitis (AS), Biostatistics, Disease Activity, Patient reported outcomes, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: In axial spondyloarthritis cohorts, patient reported outcomes are vital for tracking disease progression and response to therapy. However, many cohorts enrolled prior to the development and validation of the ASDAS-CRP as a generally accepted standard measurement of disease activity. Our goal is to formally assess if patient global assessment (PGA) activity prior to ASDAS can be used when the modern questionnaire is unavailable.

Methods: Data from the Prospective Study of Outcomes in Ankylosing Spondylitis (PSOAS) observational cohort were analyzed. Patients met Modified New York (mNY) criteria for AS and assessed their global disease activity during study visits. Before the development of ASDAS-CRP, global disease activity was rated on a numeric rating scale with the prompt: “Considering all the ways that your ankylosing spondylitis affects you, rate how you are doing.” The currently used ASDAS global prompt instead asks: “How active was your spondylitis on average during the last week?”We analyzed patients with visits that included both the older global score and the ASDAS global score to assess agreement between the two measures; ASDAS-CRP was calculated using both the older global assessment compared to the standard ASDAS global assessment. We also compared the standard ASDAS-CRP and ASDAS-ESR. We compared ASDAS disease activity categories between the comparisons and calculated weighted Cohen’s Kappa coefficients. We also compared the older vs. newer global single-item scores with intraclass correlation coefficients (ICC) to evaluate agreement.

Results: 610 unique patient visits were analyzed. The proportion of agreement of ASDAS-CRP calculated with the old PGA compared to the newer PGA was 86.7% based on disease activity categories with Cohen’s Kappa Coefficient of 0.818 (values of 0.81 – 1.00 are considered perfect agreement). The ICC was calculated using a two-way random effects model and was 0.980, consistent with excellent agreement. In other studies, the proportion of agreement of ASDAS-CRP to ASDAS-ESR has been calculated based on disease severity categories. In our study, this proportion was 72.6% with Kappa Coefficient of 0.62, which is similar to other studies.

Conclusion: Prior measures of PGA utilized before the validation of ASDAS-CRP are a valid substitution for the PGA in the ASDAS-CRP based on calculation of a Kappa Coefficient showing perfect agreement. This is important in scenarios where investigators are calculating the ASDAS-CRP in patients who were a part of observational cohorts prior to its development.

Supporting image 1Figure 1. Agreement table comparing ASDAS-CRP calculated with the previous PSOAS PGA measure and the ASDAS-CRP with standard PGA, including weighted Cohen’s kappa coefficient.

Supporting image 2Figure 2. Bland-Altman Plot assessing agreement between ASDAS-CRP calculated with the previous PSOAS PGA measure and the ASDAS-CRP with standard PGA.

Supporting image 3Figure 3. Bland-Altman plot assessing agreement between ASDAS-ESR and ASDAS-CRP


Disclosures: C. Vershel: None; M. Hwang: None; J. Reveille: Surf Therapeutics, 5; S. Kim: None; M. Brown: Clementia, 2, Grey Wolf Therapeutics, 2, Incyte, 2, Ipsen, 2, Novartis, 6, Pfizer, 2, 6, Regeneron, 2, UCB, 5, Xinthera, 2; M. Weisman: Spyre Therapeutics, 1, 2; M. Ishimori: None; M. Ward: Advanced Clinical LLC, 2, KSQ therapeutics, 2.

To cite this abstract in AMA style:

Vershel C, Hwang M, Reveille J, Kim S, Brown M, Weisman M, Ishimori M, Ward M. Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/examining-the-interchangeability-of-two-different-patient-reported-global-assessment-measures-in-an-observational-axial-spondyloarthritis-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/examining-the-interchangeability-of-two-different-patient-reported-global-assessment-measures-in-an-observational-axial-spondyloarthritis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology